A Phase 3 interventional study of ARV-471 and Fulvestrant in Advanced Breast Cancer, sponsored by Pfizer. Active, not recruiting at 312 sites in 31 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing vepdegestrant in Breast Neoplasms — 1 open to participants now, 6 under way, 2 of them phase 3. vepdegestrant · Breast Neoplasms.
Among the 12 studies testing vepdegestrant in Breast Neoplasms, this one is the 2nd largest by enrollment, is one of 6 that started in 2023, is one of 2 in phase 3, and was the 8th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →1 of the 12 studies testing vepdegestrant in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:
QuantumLeap Healthcare Collaborative · Sites in United States
Ages 18+
By country, each count listing its studies:
vepdegestrant: first FDA approval 2026 (VEPPANU). What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, vepdegestrant is the treatment under test here. Read study by study →
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 7 · Phase 3 2
First in 2010; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 624 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 48 across the 12 interventional studies. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 12 have an industry lead sponsor. The 4 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
182 studies in Breast Neoplasms by Pfizer: 6 open now, 26 under way, 7 of them phase 3. Of 145 finished, 94 (65%) have results posted.
Among the 182 studies in Breast Neoplasms by Pfizer, this one is the 11th largest by enrollment of the 121 interventional ones that give a count, is one of 7 that started in 2023, is one of 25 in phase 3, reaches primary completion later than 4 of the 25 other live ones, and was the 154th registered.
Pfizer’s Breast Neoplasms studies by the year they started, since 1998.
2 of the studies testing vepdegestrant in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05909397Phase 3PfizerVepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer | 2026-12-30 |
| NCT05548127PfizerTACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A) | 2027-03-24 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies testing vepdegestrant in Breast Neoplasms, from their registry updates:
Among Pfizer’s 182 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.
The purpose of this study is to learn about the safety and effects of the study medicine ARV-471 (PF-07850327, vepdegestrant) compared to fulvestrant (FUL) in participants with advanced breast cancer. Advanced breast cancer is difficult to cure or control with treatment. The cancer may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body, i.e. bones, lungs, brain, or liver. FUL is a medicine already used for treatment of breast cancer while ARV-471 is a new medicine.
This study is seeking participants with breast cancer who:
Half of the participants will be given ARV-471 while the other half of the participants will be given FUL.
Participants who get ARV-471 will take ARV-471 by mouth with food, one time a day. During the first treatment cycle participants who will get FUL will be given FUL by shots into the muscles on Day 1 and again 2 weeks later. After the first month, FUL shots will be given on the first day of each new treatment cycle. One treatment cycle is 28 days.
Participants will receive the study medicine until their breast cancer worsens or side effects become too severe. Participants will have visits at the study clinic about every 4 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ARV-471
Drug: Fulvestrant
orally, once daily on a 28-day continuous dosing schedule
Also known as: PF-07850327
intramuscularly on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle starting from C2D1 (28-day cycle)
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1- All Randomized Participants
PFS assessed by BICR was defined as the time from the date of randomization to the date of the first documentation of objective progression of disease (PD) per RECIST v1.1, or death due to any cause, whichever occurred first. PD as per RECIST v1.1 was defined as at least a 20% increase in the sum of diameters of target measurable lesions above nadir (smallest sum observed considering baseline and all assessments prior to the timepoint under evaluation), with a minimum absolute increase of 5 millimeters (mm) relative to nadir or unequivocal progression of existing non-target lesions or the presence of new lesions. PFS was censored on the date of last adequate disease assessment for those who did not have a PFS event, discontinued the study treatment due to withdrawal of consent prior to an event, started a new anticancer therapy prior to an event, had an event after a gap of 2 or more missing disease assessments, or lost to follow-up. Kaplan-Meier method was used.
Time frame: From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)
PFS by BICR Assessment Per RECIST v1.1-Participants With ESR1 Mutation
PFS assessed by BICR was defined as the time from the date of randomization to the date of the first documentation of objective PD per RECIST v1.1, or death due to any cause, whichever occurred first. PD as per RECIST v1.1 was defined as at least a 20% increase in the sum of diameters of target measurable lesions above nadir (smallest sum observed considering baseline and all assessments prior to the timepoint under evaluation), with a minimum absolute increase of 5 mm relative to nadir or unequivocal progression of existing non-target lesions or the presence of new lesions. PFS was censored on the date of last adequate disease assessment for those who did not have a PFS event, discontinued the study treatment due to withdrawal of consent prior to an event, started a new anticancer therapy prior to an event, had an event after a gap of 2 or more missing disease assessments, or lost to follow-up. Kaplan-Meier method was used.
Time frame: From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)
Overall Survival (OS)-All Randomized Participants
OS was defined as the time from date of randomization to date of death due to any cause. In case of no death, OS time would be censored on the date participant was last known to be alive.
Time frame: From date of randomization to the date of death due to any cause or censoring date
OS-Participants With ESR1 Mutation
OS was defined as the time from date of randomization to date of death due to any cause. In case of no death, OS time would be censored on the date participant was last known to be alive.
Time frame: From date of randomization to the date of death due to any cause or censoring date
Percentage of Participants With Objective Response (OR) by BICR Assessment- Participants With Measurable Disease at Baseline
OR was defined as the best overall response of confirmed complete response (CR) or partial response (PR) by BICR assessment as per RECIST v1.1 criteria. As per RECIST v1.1, CR was defined as complete disappearance of all target lesions, with the exception of nodal disease, complete disappearance of all non-target lesions and no new lesions. All nodes decreased to normal (short axis \<10 mm); all target lesions and disease sites were assessed. PR was defined as at least a 30% decrease from baseline in the sum of diameters of all target lesions, non-PD/not evaluated for the non-target lesions and no new lesions. The short diameter was used in the sum for nodal target lesions, while the longest diameter was used in the sum for non-nodal target lesions, all target lesions were assessed.
Time frame: From randomization until PD, death or start of new anticancer therapy, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)
Clinical Benefit Rate (CBR) by BICR Assessment
CBR: percentage of participants with clinical benefit response. Clinical benefit response: confirmed CR or PR at any time, or stable disease (SD) \>=24 weeks per RECIST v1.1. CR: complete disappearance of all target lesions, of all non-target lesions and no new lesions; except for nodal disease, all nodes decreased to normal (short axis \<10 mm); all disease sites, all target lesions assessed. PR: \>=30% decrease from baseline in sum of diameters of all target lesions, non-PD/not evaluated for non-target lesions and no new lesions; all target lesions assessed. SD: did not qualify for CR, PR, PD. All target lesions assessed. PD per RECIST v1.1: at least 20% increased sum of diameters of target measurable lesions above nadir (smallest sum observed considering baseline and all assessments prior to timepoint under evaluation), with minimum absolute increase of 5mm relative to nadir or unequivocal progression of existing non-target lesions, or new lesions.
Time frame: From randomization until PD, death due to any cause or start of new anticancer therapy, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)
Duration of Response (DOR) by BICR Assessment
DOR was defined as time from first documentation of objective tumor response (CR or PR) to first documentation of PD, or death due to any cause, whichever occurred first. CR: complete disappearance of all target lesions, of all non-target lesions and no new lesions; except for nodal disease, all nodes decreased to normal (short axis \<10 mm); all disease sites, all target lesions assessed. PR: \>=30% decrease from baseline in sum of diameters of all target lesions, non-PD/not evaluated for non-target lesions and no new lesions; all target lesions were assessed. The short diameter is used in the sum for nodal target lesions, while longest diameter is used in sum for non-nodal target lesions, all target lesions were assessed. DOR was analyzed in participants with an OR. PD: at least 20% increase in sum of diameters of target measurable lesions above nadir, with minimum absolute increase of 5 mm relative to nadir or unequivocal progression of existing non-target lesions, or new lesions.
Time frame: From first documentation of objective tumor response until confirmed PD or death, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs), Treatment Related TEAEs, Grade 3 or 4 and Grade 5 TEAEs as Assessed by NCI CTCAE v5.0
Adverse event (AE): any untoward medical occurrence in clinical study participant, temporally associated with use of study treatment, whether or not considered related to study treatment. AEs included both SAEs and all other (non-SAEs) AEs. SAE: any untoward medical occurrence, at any dose met one or more of following criteria: death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect or other important medical events. TEAEs: AEs that occur on or after first dose of study treatment up to 28 days after last dose of study treatment. Relatedness to study drug were judged by investigator. As per National Cancer Institute Common Terminology Criteria for AE (NCI CTCAE) severity of AEs were graded as following, Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life-threatening; urgent treatment indicated, Grade 5: death related to AE.
Time frame: From the first dose of study treatment up to 28 days after last dose of study treatment
Number of Participants With Grade Shift From Baseline to Maximum Post-Baseline in Hematology Parameters Assessed by NCI CTCAE v5.0
Hematological parameters including neutrophil count decreased, white blood cell decreased, anemia, platelet count decreased, hemoglobin increased and leukocytosis were assessed. Baseline was defined as the last assessment on or prior to the date of the first dose of study treatment. As per NCI CTCAE v5.0, severity was graded as, Grade 1: mild, Grade 2: moderate, Grade 3: severe and Grade 4: life-threatening; urgent treatment indicated. Grade 0: Non-missing laboratory value that fell outside the grading range for the corresponding laboratory parameter. Categories with at least 1 non-zero values showing any shift in Grade from baseline to post-baseline were reported.
Time frame: From baseline up to 28 days after last dose of study treatment (up to 19.56 months and 20.38 months for vepdegestrant and fulvestrant arms respectively)
Number of Participants With Grade Shift From Baseline to Maximum Post-Baseline in Serum Chemistry Laboratory Abnormalities Assessed by NCI CTCAE v5.0
Serum chemistry parameters including alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, cholesterol high, creatinine increased, hypercalcemia, hyperkalemia, hypermagnesemia, hypernatremia, hypertriglyceridemia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia were assessed. Baseline was defined as the last assessment on or prior to the date of the first dose of study treatment. As per NCI CTCAE v5.0 severity was graded as, Grade 1: mild, Grade 2: moderate, Grade 3: severe and Grade 4: life-threatening; urgent treatment indicated. Grade 0: Non-missing laboratory value that falls outside the grading range for the corresponding laboratory parameter. Categories with at least 1 non-zero values showing any shift in Grade from baseline to post-baseline were reported.
Time frame: From baseline up to 28 days after last dose of study treatment (up to 19.56 months and 20.38 months for vepdegestrant and fulvestrant arms respectively)
Number of Participants According to Categorization of Electrocardiogram (ECG) Parameters
Twelve lead ECGs were collected using an automated ECG machine that calculated heart rate and measured corrected QT (QTc interval, QT interval, PR interval and QRS complex). Criteria for heart rate was as follows, \<= 50 beats/minute (min), \>=100 beats/min, increase from baseline \>= 20 beats/min, decrease from baseline \>= 20 beats/min. Criteria for PR interval was \>= 220 millisecond (msec). Criteria for QRS interval was \>= 120 msec. Criteria for QT interval was as follows, \<=450 msec, \> 450 to \<= 480 msec, \>480 to \<=500 msec, \>500 msec, increase from baseline \<= 30 msec, increase from baseline \> 30 to \<= 60 msec. Criteria for QTCF interval was as follows, \<=450 msec, \> 450 to \<= 480 msec, \> 480 to \<= 500 msec, \> 500 msec, increase from baseline \<= 30 msec, increase from baseline \> 30 to \<= 60 msec, increase from baseline \> 60 msec. Baseline was defined as the last assessment on or prior to the date of the first dose of study treatment.
Time frame: From baseline up to 28 days after last dose of study treatment (up to 19.56 months and 20.38 months for vepdegestrant and fulvestrant arms respectively)
Number of Participants According to Categorization of QT Interval Corrected Using Fridericia's Formula (QTcF) Results-QTc Substudy Analysis Set
Criteria for QTcF interval for single beat were as follows, \<= 450 msec, \> 450 to \<= 480 msec, \> 480 to \<=500 msec, \> 500 msec, increase from baseline \<= 30 msec, increase from baseline \> 30 to \<= 60 msec, increase from baseline \> 60 msec. Baseline was defined as the last assessment on or prior to the date of the first dose of study treatment.
Time frame: Baseline and from the first dose of study treatment up to the end of treatment (EOT) i.e., 28 days after last dose of study treatment (approximately up to 19.56 months)
Change From Baseline in European Organization for the Research and Treatment of Cancer and Quality of Life Questionnaire (EORTC QLQ-C30) Score
The EORTC QLQ-C30 contains 30 items and is composed of 5 multi-item functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning and social functioning), 3 multi-item symptom scales (fatigue, pain and nausea/vomiting), 6 single item symptom scales (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial impact), and one global quality of life scale. This questionnaire contained 30 questions organized into 5 multi-item functional scales, 3 multi-item symptom scales, 6 single item symptom scales, and one global quality of life scale. All the scales and single-item measures range in score from 0 to 100. Higher scores on the functional scales represent higher levels of functioning. Higher scores on the global health status/quality of life scale represent higher health status/quality of life. Higher scores on symptom scales/items represent a greater presence of symptoms.
Time frame: From baseline up to 28 days after last dose of study treatment
Change From Baseline in European Organization for the Research and Treatment of Cancer and Quality of Life Questionnaire-Breast Cancer Specific (EORTC QLQ-BR23) Score
The EORTC QLQ-BR23 was a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consisted of four functional scales (body image, sexual functioning, sexual enjoyment, future perspective) and four symptom scales (systemic side-effects, breast symptoms, arm symptoms, upset by hair loss). Each item was rated by choosing 1 of 4 possible responses that record the level of intensity (1= not at all, 2= a little, 3= quite a bit, and 4= very much) within each scale. All scores are converted to a 0 to 100 scale. For functional scales, higher scores represent a better level of functioning. For symptom-oriented scales, higher scores represented greater symptom severity.
Time frame: From baseline up to 28 days after last dose of study treatment
Change From Baseline in EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Index and Visual Analogue Scale (VAS) Scores
The EQ-5D-5L was a 5-item participant-completed questionnaire designed to assess health status in terms of a single index value or utility score. There were 2 components, a Health State Profile where participants rated their level of problems (1=none, 2=slight, 3=moderate, 4=severe, 5=extreme/unable) in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), and a visual analogue scale (VAS) in which participants rated their overall health status from 0 (worst imaginable) to 100 (best imaginable). Responses to 5 dimensions comprised health state/ single utility index value. E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with a predefined index value to it. Every health state (coded as combination of responses) had a unique predefined utility index value assigned to it per US value sets, Overall index scores ranged from 0 to 1, with lower scores representing a higher level of dysfunction.
Time frame: From baseline up to 28 days after last dose of study treatment
Change From Baseline in Pain Severity and Pain Interference as Assessed by Brief Pain Inventory Short Form (BPI-SF) Score
The BPI-SF consisted of items to measure participant perceptions of pain severity (item 3), assess degree of interference of pain on daily functioning, body diagrams on which participants indicate location of pain, record pain medication usage, VAS assessed degree of pain relief in last 24 hours (item 9a). Items in pain severity scale evaluated pain "at its worst", "at its least", and "on average" over previous 24 hours, as well as "pain now" (at time of assessment). Participants responded on 10- point numerical rating scale, where 0 = "no pain" and 10 = "pain as bad as you can imagine". Pain interference scale asked participants to rate how their pain interferes with "enjoyment of life", "general activity", "walking ability", "mood", "sleep", "normal work" and "relations with other people." Responses for interference scale were also based on 10-points scale, where 0 = "does not interfere" and 10 = "interferes completely". Higher scores=high levels of pain, impact attributed to pain.
Time frame: From baseline up to 28 days after last dose of study treatment
Plasma Concentration of ARV-471 and Its Epimer ARV-473
Plasma concentrations of ARV-471 and its epimer ARV-473 were reported in this outcome measure.
Time frame: Anytime between -4 to 0 hours on Day 1 of Cycle 2, Cycle 3, Cycle 5 and Cycle 7 and anytime between 5 to 7 hours on Day 1 of Cycle 2 and Cycle 3
Change in Plasma Circulating Tumor DNA (ctDNA) From Baseline
Quantitative change in plasma ctDNA levels from baseline to each protocol specified time point (up to EOT), as assessed using a validated assay.
Time frame: Baseline and up to EOT
Participants with estrogen receptor (ER) positive, human epidermal growth factor receptor 2 negative (HER2-) unresectable locoregional recurrent or metastatic breast cancer (mBC) not amenable to radiotherapy with curative intent who progressed after prior endocrine based treatment(s) for advanced disease were included in this study.
| Milestone | Vepdegestrant (ARV-471) | Fulvestrant |
|---|---|---|
| Started | 313 | 311 |
| Treated | 312 | 307 |
| Completed | 0 | 0 |
| Not completed | 313 | 311 |
| Withdrew: Randomized but not treated | 1 | 4 |
| Withdrew: Adverse event | 7 | 2 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Physician decision | 2 | 3 |
| Withdrew: Progressive disease | 189 | 209 |
| Withdrew: Protocol violation | 2 | 0 |
| Withdrew: Withdrawal by subject | 9 | 7 |
| Withdrew: Global deterioration of health status | 5 | 9 |
| Withdrew: Other | 0 | 1 |
| Withdrew: Ongoing | 96 | 76 |
| Milestone | Vepdegestrant (ARV-471) | Fulvestrant |
|---|---|---|
| Started | 205 | 224 |
| Completed | 0 | 0 |
| Not completed | 205 | 224 |
| Withdrew: Death | 43 | 35 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Ongoing | 161 | 186 |
PFS assessed by BICR was defined as the time from the date of randomization to the date of the first documentation of objective progression of disease (PD) per RECIST v1.1, or death due to any cause, whichever occurred first. PD as per RECIST v1.1 was defined as at least a 20% increase in the sum of diameters of target measurable lesions above nadir (smallest sum observed considering baseline and all assessments prior to the timepoint under evaluation), with a minimum absolute increase of 5 millimeters (mm) relative to nadir or unequivocal progression of existing non-target lesions or the presence of new lesions. PFS was censored on the date of last adequate disease assessment for those who did not have a PFS event, discontinued the study treatment due to withdrawal of consent prior to an event, started a new anticancer therapy prior to an event, had an event after a gap of 2 or more missing disease assessments, or lost to follow-up. Kaplan-Meier method was used.
| Months | Vepdegestrant | Fulvestrant |
|---|---|---|
| Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1- All Randomized Participants | 3.7 (3.6 to 5.3) | 3.6 (2.2 to 3.8) |
PFS assessed by BICR was defined as the time from the date of randomization to the date of the first documentation of objective PD per RECIST v1.1, or death due to any cause, whichever occurred first. PD as per RECIST v1.1 was defined as at least a 20% increase in the sum of diameters of target measurable lesions above nadir (smallest sum observed considering baseline and all assessments prior to the timepoint under evaluation), with a minimum absolute increase of 5 mm relative to nadir or unequivocal progression of existing non-target lesions or the presence of new lesions. PFS was censored on the date of last adequate disease assessment for those who did not have a PFS event, discontinued the study treatment due to withdrawal of consent prior to an event, started a new anticancer therapy prior to an event, had an event after a gap of 2 or more missing disease assessments, or lost to follow-up. Kaplan-Meier method was used.
| Months | Vepdegestrant | Fulvestrant |
|---|---|---|
| PFS by BICR Assessment Per RECIST v1.1-Participants With ESR1 Mutation | 5.0 (3.7 to 7.4) | 2.1 (1.9 to 3.5) |
OS was defined as the time from date of randomization to date of death due to any cause. In case of no death, OS time would be censored on the date participant was last known to be alive.
Results for this outcome have not been posted.
OS was defined as the time from date of randomization to date of death due to any cause. In case of no death, OS time would be censored on the date participant was last known to be alive.
Results for this outcome have not been posted.
OR was defined as the best overall response of confirmed complete response (CR) or partial response (PR) by BICR assessment as per RECIST v1.1 criteria. As per RECIST v1.1, CR was defined as complete disappearance of all target lesions, with the exception of nodal disease, complete disappearance of all non-target lesions and no new lesions. All nodes decreased to normal (short axis \<10 mm); all target lesions and disease sites were assessed. PR was defined as at least a 30% decrease from baseline in the sum of diameters of all target lesions, non-PD/not evaluated for the non-target lesions and no new lesions. The short diameter was used in the sum for nodal target lesions, while the longest diameter was used in the sum for non-nodal target lesions, all target lesions were assessed.
| Percentage of participants | Vepdegestrant | Fulvestrant |
|---|---|---|
| Percentage of Participants With Objective Response (OR) by BICR Assessment- Participants With Measurable Disease at Baseline | 10.9 (7.4 to 15.6) | 3.6 (1.8 to 6.9) |
CBR: percentage of participants with clinical benefit response. Clinical benefit response: confirmed CR or PR at any time, or stable disease (SD) \>=24 weeks per RECIST v1.1. CR: complete disappearance of all target lesions, of all non-target lesions and no new lesions; except for nodal disease, all nodes decreased to normal (short axis \<10 mm); all disease sites, all target lesions assessed. PR: \>=30% decrease from baseline in sum of diameters of all target lesions, non-PD/not evaluated for non-target lesions and no new lesions; all target lesions assessed. SD: did not qualify for CR, PR, PD. All target lesions assessed. PD per RECIST v1.1: at least 20% increased sum of diameters of target measurable lesions above nadir (smallest sum observed considering baseline and all assessments prior to timepoint under evaluation), with minimum absolute increase of 5mm relative to nadir or unequivocal progression of existing non-target lesions, or new lesions.
| Percentage of participants | Vepdegestrant | Fulvestrant |
|---|---|---|
| Clinical Benefit Rate (CBR) by BICR Assessment | 34.3 (28.9 to 40.1) | 28.7 (23.6 to 34.3) |
DOR was defined as time from first documentation of objective tumor response (CR or PR) to first documentation of PD, or death due to any cause, whichever occurred first. CR: complete disappearance of all target lesions, of all non-target lesions and no new lesions; except for nodal disease, all nodes decreased to normal (short axis \<10 mm); all disease sites, all target lesions assessed. PR: \>=30% decrease from baseline in sum of diameters of all target lesions, non-PD/not evaluated for non-target lesions and no new lesions; all target lesions were assessed. The short diameter is used in the sum for nodal target lesions, while longest diameter is used in sum for non-nodal target lesions, all target lesions were assessed. DOR was analyzed in participants with an OR. PD: at least 20% increase in sum of diameters of target measurable lesions above nadir, with minimum absolute increase of 5 mm relative to nadir or unequivocal progression of existing non-target lesions, or new lesions.
| Months | Vepdegestrant | Fulvestrant |
|---|---|---|
| Duration of Response (DOR) by BICR Assessment | NA (5.6 to NA) | 7.4 (5.6 to NA) |
Adverse event (AE): any untoward medical occurrence in clinical study participant, temporally associated with use of study treatment, whether or not considered related to study treatment. AEs included both SAEs and all other (non-SAEs) AEs. SAE: any untoward medical occurrence, at any dose met one or more of following criteria: death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect or other important medical events. TEAEs: AEs that occur on or after first dose of study treatment up to 28 days after last dose of study treatment. Relatedness to study drug were judged by investigator. As per National Cancer Institute Common Terminology Criteria for AE (NCI CTCAE) severity of AEs were graded as following, Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life-threatening; urgent treatment indicated, Grade 5: death related to AE.
Results for this outcome have not been posted.
Hematological parameters including neutrophil count decreased, white blood cell decreased, anemia, platelet count decreased, hemoglobin increased and leukocytosis were assessed. Baseline was defined as the last assessment on or prior to the date of the first dose of study treatment. As per NCI CTCAE v5.0, severity was graded as, Grade 1: mild, Grade 2: moderate, Grade 3: severe and Grade 4: life-threatening; urgent treatment indicated. Grade 0: Non-missing laboratory value that fell outside the grading range for the corresponding laboratory parameter. Categories with at least 1 non-zero values showing any shift in Grade from baseline to post-baseline were reported.
| Participants | Vepdegestrant (ARV-471) | Fulvestrant |
|---|---|---|
| Neutrophil count decreased Grade 0 to Grade 1 | 33 | 13 |
| Neutrophil count decreased Grade 0 to Grade 2 | 26 | 15 |
| Neutrophil count decreased Grade 0 to Grade 3 | 4 | 0 |
| Neutrophil count decreased Grade 0 to Grade 4 | 1 | 1 |
| Neutrophil count decreased Grade 1 to Grade 0 | 5 | 9 |
| Neutrophil count decreased Grade 1 to Grade 2 | 5 | 3 |
| Neutrophil count decreased Grade 1 to Grade 3 | 1 | 1 |
| Neutrophil count decreased Grade 2 to Grade 0 | 2 | 1 |
| Neutrophil count decreased Grade 3 to Grade 2 | 0 | 1 |
| White blood cell decreased Grade 0 to Grade 1 | 68 | 31 |
| White blood cell decreased Grade 0 to Grade 2 | 18 | 8 |
| White blood cell decreased Grade 0 to Grade 3 | 1 | 1 |
| White blood cell decreased Grade 1 to Grade 0 | 10 | 12 |
| White blood cell decreased Grade 1 to Grade 2 | 10 | 2 |
| White blood cell decreased Grade 1 to Grade 3 | 0 | 1 |
| White blood cell decreased Grade 2 to Grade 0 | 2 | 3 |
| White blood cell decreased Grade 2 to Grade 1 | 0 | 1 |
| Anemia Grade 0 to Grade 1 | 38 | 33 |
| Anemia Grade 0 to Grade 2 | 6 | 6 |
| Anemia Grade 0 to Grade 3 | 1 | 1 |
| Anemia Grade 1 to Grade 0 | 14 | 12 |
| Anemia Grade 1 to Grade 2 | 17 | 11 |
| Anemia Grade 1 to Grade 3 | 4 | 4 |
| Anemia Grade 2 to Grade 0 | 1 | 1 |
| Anemia Grade 2 to Grade 1 | 5 | 3 |
| Anemia Grade 2 to Grade 3 | 2 | 5 |
| Platelet count decreased Grade 0 to Grade 1 | 25 | 22 |
| Platelet count decreased Grade 0 to Grade 2 | 2 | 3 |
| Platelet count decreased Grade 0 to Grade 3 | 2 | 2 |
| Platelet count decreased Grade 1 to Grade 0 | 3 | 1 |
| Platelet count decreased Grade 1 to Grade 2 | 0 | 1 |
| Platelet count decreased Grade 1 to Grade 3 | 1 | 0 |
| Hemoglobin increased Grade 0 to Grade 1 | 8 | 3 |
| Hemoglobin increased Grade 0 to Grade 2 | 1 | 0 |
Serum chemistry parameters including alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, cholesterol high, creatinine increased, hypercalcemia, hyperkalemia, hypermagnesemia, hypernatremia, hypertriglyceridemia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia were assessed. Baseline was defined as the last assessment on or prior to the date of the first dose of study treatment. As per NCI CTCAE v5.0 severity was graded as, Grade 1: mild, Grade 2: moderate, Grade 3: severe and Grade 4: life-threatening; urgent treatment indicated. Grade 0: Non-missing laboratory value that falls outside the grading range for the corresponding laboratory parameter. Categories with at least 1 non-zero values showing any shift in Grade from baseline to post-baseline were reported.
| Participants | Vepdegestrant (ARV-471) | Fulvestrant |
|---|---|---|
| Alanine aminotransferase increased Grade 0 to Grade 1 | 55 | 50 |
| Alanine aminotransferase increased Grade 0 to Grade 2 | 6 | 5 |
| Alanine aminotransferase increased Grade 0 to Grade 3 | 2 | 0 |
| Alanine aminotransferase increased Grade 1 to Grade 0 | 52 | 72 |
| Alanine aminotransferase increased Grade 1 to Grade 2 | 3 | 4 |
| Alanine aminotransferase increased Grade 1 to Grade 3 | 0 | 3 |
| Alanine aminotransferase increased Grade 2 to Grade 0 | 6 | 9 |
| Alanine aminotransferase increased Grade 2 to Grade 1 | 1 | 0 |
| Alkaline phosphatase increased Grade 0 to Grade 1 | 51 | 53 |
| Alkaline phosphatase increased Grade 0 to Grade 2 | 1 | 5 |
| Alkaline phosphatase increased Grade 1 to Grade 0 | 53 | 52 |
| Alkaline phosphatase increased Grade 1 to Grade 2 | 8 | 7 |
| Alkaline phosphatase increased Grade 2 to Grade 0 | 0 | 3 |
| Alkaline phosphatase increased Grade 2 to Grade 1 | 0 | 1 |
| Alkaline phosphatase increased Grade 2 to Grade 3 | 0 | 1 |
| Aspartate aminotransferase increased Grade 0 to Grade 1 | 78 | 54 |
| Aspartate aminotransferase increased Grade 0 to Grade 2 | 2 | 4 |
| Aspartate aminotransferase increased Grade 0 to Grade 3 | 0 | 1 |
| Aspartate aminotransferase increased Grade 1 to Grade 0 | 76 | 84 |
| Aspartate aminotransferase increased Grade 1 to Grade 2 | 4 | 5 |
| Aspartate aminotransferase increased Grade 1 to Grade 3 | 5 | 4 |
| Aspartate aminotransferase increased Grade 2 to Grade 0 | 6 | 2 |
| Aspartate aminotransferase increased Grade 2 to Grade 1 | 0 | 3 |
| Aspartate aminotransferase increased Grade 3 to Grade 0 | 0 | 1 |
| Blood bilirubin increased Grade 0 to Grade 1 | 30 | 12 |
| Blood bilirubin increased Grade 0 to Grade 2 | 9 | 7 |
| Blood bilirubin increased Grade 0 to Grade 3 | 1 | 3 |
| Blood bilirubin increased Grade 0 to Grade 4 | 2 | 0 |
| Blood bilirubin increased Grade 1 to Grade 0 | 0 | 4 |
| Blood bilirubin increased Grade 1 to Grade 2 | 1 | 0 |
| Blood bilirubin increased Grade 1 to Grade 3 | 0 | 1 |
| Blood bilirubin increased Grade 2 to Grade 0 | 1 | 0 |
| Cholesterol high Grade 0 to Grade 1 | 22 | 31 |
| Cholesterol high Grade 1 to Grade 0 | 23 | 20 |
| Cholesterol high Grade 1 to Grade 2 | 3 | 6 |
| Cholesterol high Grade 1 to Grade 3 | 0 | 1 |
| Cholesterol high Grade 2 to Grade 0 | 1 | 0 |
| Cholesterol high Grade 2 to Grade 1 | 4 | 0 |
| Creatinine increased Grade 0 to Grade 1 | 26 | 22 |
| Creatinine increased Grade 0 to Grade 2 | 8 | 9 |
| Creatinine increased Grade 0 to Grade 3 | 0 | 1 |
| Creatinine increased Grade 1 to Grade 0 | 8 | 6 |
| Creatinine increased Grade 1 to Grade 2 | 2 | 0 |
| Creatinine increased Grade 1 to Grade 3 | 0 | 1 |
| Creatinine increased Grade 2 to Grade 1 | 0 | 1 |
| Hypercalcemia Grade 0 to Grade 1 | 24 | 21 |
| Hypercalcemia Grade 0 to Grade 2 | 2 | 0 |
| Hypercalcemia Grade 0 to Grade 3 | 1 | 0 |
| Hypercalcemia Grade 0 to Grade 4 | 1 | 0 |
| Hypercalcemia Grade 1 to Grade 0 | 4 | 3 |
| Hypercalcemia Grade 1 to Grade 2 | 1 | 0 |
| Hypercalcemia Grade 1 to Grade 3 | 0 | 1 |
| Hypercalcemia Grade 1 to Grade 4 | 1 | 1 |
| Hyperkalemia Grade 0 to Grade 1 | 21 | 24 |
| Hyperkalemia Grade 0 to Grade 2 | 4 | 3 |
| Hyperkalemia Grade 1 to Grade 0 | 6 | 5 |
| Hyperkalemia Grade 1 to Grade 2 | 1 | 0 |
| Hypermagnesemia Grade 0 to Grade 1 | 10 | 9 |
| Hypermagnesemia Grade 0 to Grade 3 | 1 | 0 |
| Hypermagnesemia Grade 1 to Grade 0 | 2 | 3 |
| Hypermagnesemia Grade 3 to Grade 1 | 0 | 1 |
| Hypernatremia Grade 0 to Grade 1 | 11 | 4 |
| Hypernatremia Grade 0 to Grade 2 | 1 | 0 |
| Hypernatremia Grade 1 to Grade 0 | 1 | 1 |
| Hypertriglyceridemia Grade 0 to Grade 1 | 41 | 36 |
| Hypertriglyceridemia Grade 0 to Grade 2 | 2 | 2 |
| Hypertriglyceridemia Grade 0 to Grade 3 | 1 | 0 |
| Hypertriglyceridemia Grade 1 to Grade 0 | 19 | 11 |
| Hypertriglyceridemia Grade 1 to Grade 2 | 9 | 5 |
| Hypertriglyceridemia Grade 1 to Grade 3 | 2 | 0 |
| Hypertriglyceridemia Grade 2 to Grade 0 | 0 | 1 |
| Hypertriglyceridemia Grade 2 to Grade 1 | 3 | 1 |
| Hypertriglyceridemia Grade 2 to Grade 3 | 0 | 1 |
| Hypertriglyceridemia Grade 3 to Grade 4 | 0 | 1 |
| Hypoalbuminemia Grade 0 to Grade 1 | 40 | 32 |
| Hypoalbuminemia Grade 0 to Grade 2 | 5 | 8 |
| Hypoalbuminemia Grade 1 to Grade 0 | 4 | 8 |
| Hypoalbuminemia Grade 1 to Grade 2 | 1 | 3 |
| Hypoalbuminemia Grade 1 to Grade 3 | 0 | 1 |
| Hypoalbuminemia Grade 2 to Grade 0 | 1 | 0 |
| Hypoalbuminemia Grade 2 to Grade 1 | 1 | 0 |
| Hypoalbuminemia Grade 2 to Grade 3 | 0 | 1 |
| Hypocalcemia Grade 0 to Grade 1 | 26 | 20 |
| Hypocalcemia Grade 0 to Grade 2 | 1 | 3 |
| Hypocalcemia Grade 0 to Grade 3 | 0 | 1 |
| Hypocalcemia Grade 1 to Grade 0 | 5 | 5 |
| Hypocalcemia Grade 1 to Grade 2 | 4 | 1 |
| Hypocalcemia Grade 2 to Grade 1 | 1 | 0 |
| Hypoglycemia Grade 0 to Grade 1 | 6 | 9 |
| Hypoglycemia Grade 0 to Grade 2 | 1 | 0 |
| Hypoglycemia Grade 1 to Grade 0 | 2 | 1 |
| Hypokalemia Grade 0 to Grade 2 | 32 | 18 |
| Hypokalemia Grade 0 to Grade 3 | 4 | 0 |
| Hypokalemia Grade 2 to Grade 0 | 0 | 1 |
| Hypokalemia Grade 2 to Grade 3 | 3 | 0 |
| Hypokalemia Grade 3 to Grade 0 | 0 | 1 |
| Hypomagnesemia Grade 0 to Grade 1 | 19 | 12 |
| Hypomagnesemia Grade 0 to Grade 2 | 2 | 0 |
| Hypomagnesemia Grade 1 to Grade 0 | 3 | 1 |
| Hypomagnesemia Grade 1 to Grade 2 | 2 | 0 |
| Hypomagnesemia Grade 2 to Grade 3 | 1 | 0 |
| Hyponatremia Grade 0 to Grade 1 | 34 | 32 |
| Hyponatremia Grade 0 to Grade 3 | 4 | 2 |
| Hyponatremia Grade 1 to Grade 0 | 7 | 8 |
| Hyponatremia Grade 1 to Grade 3 | 1 | 0 |
| Hyponatremia Grade 3 to Grade 0 | 1 | 0 |
| Hyponatremia Grade 3 to Grade 1 | 0 | 1 |
Twelve lead ECGs were collected using an automated ECG machine that calculated heart rate and measured corrected QT (QTc interval, QT interval, PR interval and QRS complex). Criteria for heart rate was as follows, \<= 50 beats/minute (min), \>=100 beats/min, increase from baseline \>= 20 beats/min, decrease from baseline \>= 20 beats/min. Criteria for PR interval was \>= 220 millisecond (msec). Criteria for QRS interval was \>= 120 msec. Criteria for QT interval was as follows, \<=450 msec, \> 450 to \<= 480 msec, \>480 to \<=500 msec, \>500 msec, increase from baseline \<= 30 msec, increase from baseline \> 30 to \<= 60 msec. Criteria for QTCF interval was as follows, \<=450 msec, \> 450 to \<= 480 msec, \> 480 to \<= 500 msec, \> 500 msec, increase from baseline \<= 30 msec, increase from baseline \> 30 to \<= 60 msec, increase from baseline \> 60 msec. Baseline was defined as the last assessment on or prior to the date of the first dose of study treatment.
| Participants | Vepdegestrant (ARV-471) | Fulvestrant |
|---|---|---|
| Heart rate <= 50 beats/min | 4 | 1 |
| Heart rate >= 100 beats/min | 23 | 19 |
| Heart rate increase from baseline >=20 beats/min | 17 | 15 |
| Heart rate decrease from baseline >=20 beats/min | 22 | 10 |
| PR interval >= 220 msec | 4 | 4 |
| QRS interval >=120 msec | 6 | 10 |
| QT interval <=450 msec | 232 | 278 |
| QT interval >450 to <=480 msec | 53 | 19 |
| QT interval >480 to <=500 msec | 16 | 4 |
| QT interval > 500 msec | 8 | 0 |
| QT intervals increase from baseline <= 30 msec | 171 | 267 |
| QT intervals increase from baseline > 30 to <=60 msec | 111 | 28 |
| QT intervals increase from baseline > 60 msec | 26 | 6 |
| QTcF interval <=450 msec | 177 | 260 |
| QTcF interval >450 to <=480 msec | 116 | 38 |
| QTcF interval >480 to <=500 msec | 11 | 1 |
| QTcF interval > 500 msec | 5 | 2 |
| QTcF interval increase from baseline <= 30 msec | 228 | 291 |
| QTcF interval increase from baseline > 30 to <= 60 msec | 71 | 9 |
| QTcF interval increase from baseline > 60 msec | 8 | 1 |
Criteria for QTcF interval for single beat were as follows, \<= 450 msec, \> 450 to \<= 480 msec, \> 480 to \<=500 msec, \> 500 msec, increase from baseline \<= 30 msec, increase from baseline \> 30 to \<= 60 msec, increase from baseline \> 60 msec. Baseline was defined as the last assessment on or prior to the date of the first dose of study treatment.
| Participants | Vepdegestrant (ARV-471) |
|---|---|
| QTcF interval for single beat <=450 msec | 63 |
| QTcF interval for single beat > 450 to <= 480 msec | 24 |
| QTcF interval for single beat >480 to <=500 msec | 0 |
| QTcF interval for single beat > 500 msec | 1 |
| QTcF interval for single beat increase from baseline <= 30 msec | 67 |
| QTcF interval for single beat increase from baseline >30 to <= 60 msec | 21 |
| QTcF interval for single beat increase from baseline > 60 msec | 0 |
The EORTC QLQ-C30 contains 30 items and is composed of 5 multi-item functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning and social functioning), 3 multi-item symptom scales (fatigue, pain and nausea/vomiting), 6 single item symptom scales (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial impact), and one global quality of life scale. This questionnaire contained 30 questions organized into 5 multi-item functional scales, 3 multi-item symptom scales, 6 single item symptom scales, and one global quality of life scale. All the scales and single-item measures range in score from 0 to 100. Higher scores on the functional scales represent higher levels of functioning. Higher scores on the global health status/quality of life scale represent higher health status/quality of life. Higher scores on symptom scales/items represent a greater presence of symptoms.
Results for this outcome have not been posted.
The EORTC QLQ-BR23 was a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consisted of four functional scales (body image, sexual functioning, sexual enjoyment, future perspective) and four symptom scales (systemic side-effects, breast symptoms, arm symptoms, upset by hair loss). Each item was rated by choosing 1 of 4 possible responses that record the level of intensity (1= not at all, 2= a little, 3= quite a bit, and 4= very much) within each scale. All scores are converted to a 0 to 100 scale. For functional scales, higher scores represent a better level of functioning. For symptom-oriented scales, higher scores represented greater symptom severity.
Results for this outcome have not been posted.
The EQ-5D-5L was a 5-item participant-completed questionnaire designed to assess health status in terms of a single index value or utility score. There were 2 components, a Health State Profile where participants rated their level of problems (1=none, 2=slight, 3=moderate, 4=severe, 5=extreme/unable) in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), and a visual analogue scale (VAS) in which participants rated their overall health status from 0 (worst imaginable) to 100 (best imaginable). Responses to 5 dimensions comprised health state/ single utility index value. E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with a predefined index value to it. Every health state (coded as combination of responses) had a unique predefined utility index value assigned to it per US value sets, Overall index scores ranged from 0 to 1, with lower scores representing a higher level of dysfunction.
Results for this outcome have not been posted.
The BPI-SF consisted of items to measure participant perceptions of pain severity (item 3), assess degree of interference of pain on daily functioning, body diagrams on which participants indicate location of pain, record pain medication usage, VAS assessed degree of pain relief in last 24 hours (item 9a). Items in pain severity scale evaluated pain "at its worst", "at its least", and "on average" over previous 24 hours, as well as "pain now" (at time of assessment). Participants responded on 10- point numerical rating scale, where 0 = "no pain" and 10 = "pain as bad as you can imagine". Pain interference scale asked participants to rate how their pain interferes with "enjoyment of life", "general activity", "walking ability", "mood", "sleep", "normal work" and "relations with other people." Responses for interference scale were also based on 10-points scale, where 0 = "does not interfere" and 10 = "interferes completely". Higher scores=high levels of pain, impact attributed to pain.
Results for this outcome have not been posted.
Plasma concentrations of ARV-471 and its epimer ARV-473 were reported in this outcome measure.
| Nanograms per milliliter | Vepdegestrant (ARV-471) |
|---|---|
| ARV-471: Cycle 2 Day 1 (-4 to 0 hours) | 445.5 (3.05 to 1530) |
| ARV-471: Cycle 2 Day 1 (5 to 7 hours) | 795.5 (50.5 to 2260) |
| ARV-471: Cycle 3 Day 1 (-4 to 0 hours) | 453.5 (11.5 to 1680) |
| ARV-471: Cycle 3 Day 1 (5 to 7 hours) | 743.0 (151 to 2170) |
| ARV-471: Cycle 5 Day 1 (-4 to 0 hours) | 440.5 (0.00 to 1370) |
| ARV-471: Cycle 7 Day 1 (-4 to 0 hours) | 466.0 (18.7 to 1130) |
| ARV-473: Cycle 2 Day 1 (-4 to 0 hours) | 193.5 (0.00 to 628) |
| ARV-473: Cycle 2 Day 1 (5 to 7 hours) | 225.5 (19.3 to 700) |
| ARV-473: Cycle 3 Day 1 (-4 to 0 hours) | 193.0 (6.10 to 611) |
| ARV-473: Cycle 3 Day 1 (5 to 7 hours) | 214.0 (26.0 to 655) |
| ARV-473: Cycle 5 Day 1 (-4 to 0 hours) | 188.0 (0.00 to 561) |
| ARV-473: Cycle 7 Day 1 (-4 to 0 hours) | 186.0 (10.3 to 464) |
Quantitative change in plasma ctDNA levels from baseline to each protocol specified time point (up to EOT), as assessed using a validated assay.
Results for this outcome have not been posted.
Collected over Adverse events: From the first dose of study treatment up to 28 days after last dose of study treatment (up to 19.56 months and 20.38 months for vepdegestrant and fulvestrant arms respectively); All-cause mortality: From randomization until date of death due to any cause (up to 19.56 months and 20.38 months for vepdegestrant and fulvestrant arms respectively). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vepdegestrant (ARV-471) | 45/313 (14.4%) | 32/312 (10.3%) | 233/312 (74.7%) |
| Fulvestrant | 35/311 (11.3%) | 28/307 (9.1%) | 174/307 (56.7%) |
| Event | Vepdegestrant (ARV-471) | Fulvestrant |
|---|---|---|
| Disease progressionGeneral disorders | 4/312 | 1/307 |
| VomitingGastrointestinal disorders | 0/312 | 3/307 |
| AnaemiaBlood and lymphatic system disorders | 0/312 | 2/307 |
| FallInjury, poisoning and procedural complications | 2/312 | 2/307 |
| PneumoniaInfections and infestations | 2/312 | 1/307 |
| Femoral neck fractureInjury, poisoning and procedural complications | 2/312 | 1/307 |
| Lumbar vertebral fractureInjury, poisoning and procedural complications | 2/312 | 0/307 |
| HypercalcaemiaMetabolism and nutrition disorders | 2/312 | 1/307 |
| ArrhythmiaCardiac disorders | 0/312 | 1/307 |
| Atrial fibrillationCardiac disorders | 0/312 | 1/307 |
| Event | Vepdegestrant (ARV-471) | Fulvestrant |
|---|---|---|
| FatigueGeneral disorders | 49/312 | 23/307 |
| Alanine aminotransferase increasedInvestigations | 45/312 | 30/307 |
| Aspartate aminotransferase increasedInvestigations | 45/312 | 32/307 |
| NauseaGastrointestinal disorders | 42/312 | 27/307 |
| AnaemiaBlood and lymphatic system disorders | 36/312 | 21/307 |
| AstheniaGeneral disorders | 35/312 | 26/307 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 33/312 | 33/307 |
| Decreased appetiteMetabolism and nutrition disorders | 33/312 | 16/307 |
| Back painMusculoskeletal and connective tissue disorders | 33/312 | 20/307 |
| ConstipationGastrointestinal disorders | 31/312 | 10/307 |
| Age, Continuous(Years) | Vepdegestrant (ARV-471) | Fulvestrant | Total |
|---|---|---|---|
| Mean | 60.3 ± 12.09 | 60.3 ± 11.52 | 60.3 ± 11.8 |
| Sex: Female, Male(Participants) | Vepdegestrant (ARV-471) | Fulvestrant | Total |
|---|---|---|---|
| Female | 311 | 310 | 621 |
| Male | 2 | 1 | 3 |
| Ethnicity (NIH/OMB)(Participants) | Vepdegestrant (ARV-471) | Fulvestrant | Total |
|---|---|---|---|
| Hispanic or Latino | 29 | 36 | 65 |
| Not Hispanic or Latino | 241 | 240 | 481 |
| Unknown or Not Reported | 43 | 35 | 78 |
| Race (NIH/OMB)(Participants) | Vepdegestrant (ARV-471) | Fulvestrant | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 4 | 5 |
| Asian | 122 | 129 | 251 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 6 | 11 |
| White | 148 | 143 | 291 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 37 | 29 | 66 |
Showing the first 100 of 312 sites across 31 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Mar 2023 to primary completion in Jan 2025, 22 months.
Results were first posted in Feb 2026, 1 year after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 22 months is below that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vepdegestrant